Strumento inattivo

Azioni Tobira Therapeutics Inc Nasdaq

Azioni

Durata

Periodo

Stile

TOBIRA fait gagner plus de 40 000 euros à un investisseur !	26/10/16
Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20/10/16
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03/10/16
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21/09/16
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20/09/16

Dirigenti	Titolo	Età	Da
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9,42%	115 Mrd
REGENERON PHARMACEUTICALS, INC.	+11,84%	106 Mrd
ARGENX SE	-1,05%	21,96 Mrd
BIONTECH SE	-14,15%	21,84 Mrd
GENMAB A/S	-5,29%	19,21 Mrd
BEIGENE, LTD.	-4,16%	18,08 Mrd
WUXI APPTEC CO., LTD.	-38,29%	17,71 Mrd
NEUROCRINE BIOSCIENCES, INC.	+7,99%	14,32 Mrd
SAREPTA THERAPEUTICS, INC.	+36,24%	12,42 Mrd